NB004 / Newbay Pharma - LARVOL DELTA

Lead Optimization Yielding a pan-Pim Inhibitor GDC-0570/NB004 for Cancer Treatment in the Clinical Testing (ACS-Sp 2024) - "The structure of GDC-0570 has not been disclosed. Currently, GDC-0570 is in active Phase 1 clinical trial."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Ningbo Newbay Technology Development Co., Ltd | N=36 ➔ 120 | Trial completion date: Sep 2023 ➔ Jun 2025 | Trial primary completion date: May 2023 ➔ Feb 2025

Combination therapy • Enrollment change • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Discovery of GDC-0570/NB004 as a second-generation pan-Pim inhibitor through extensive optimization for cancer treatment (ACS-Fall 2023) - "This is the first time that the structure of GDC-0570 will be fully disclosed. Currently, GDC-0570 is in active phase 1 clinical trial."

Hematological Malignancies • Multiple Myeloma • Oncology